|
JP2001518290A
(en)
|
1997-09-29 |
2001-10-16 |
ポイント セラピューティクス, インコーポレイテッド |
Stimulation of hematopoietic cells in vitro
|
|
US6979697B1
(en)
|
1998-08-21 |
2005-12-27 |
Point Therapeutics, Inc. |
Regulation of substrate activity
|
|
US20030096391A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Millennium Pharmaceuticals, Inc. |
17903, a novel human aminopeptidase and uses therefor
|
|
DE60043783D1
(en)
*
|
1999-11-11 |
2010-03-18 |
Astellas Pharma Inc |
METALOPROTEASE WITH AGGRECANASE ACTIVITY
|
|
US7700341B2
(en)
|
2000-02-03 |
2010-04-20 |
Dendreon Corporation |
Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
|
|
WO2001079473A2
(en)
*
|
2000-04-18 |
2001-10-25 |
Millennium Pharmaceuticals, Inc. |
21953, a human prolyl oligopeptidase family member and uses thereof
|
|
US20030083244A1
(en)
*
|
2000-04-26 |
2003-05-01 |
Vernet Corine A.M. |
Novel proteins and nucleic acids encoding same
|
|
EP1294901A2
(en)
*
|
2000-05-04 |
2003-03-26 |
Sugen, Inc. |
Novel proteases
|
|
ATE317399T1
(en)
*
|
2000-06-23 |
2006-02-15 |
|
REGULATION OF HUMAN PROSTASIN-LIKE SERINE PROTEASE
|
|
US20040132023A1
(en)
|
2000-06-26 |
2004-07-08 |
Shyam Ramakrishnan |
Regulation of human caspase-1-like protease
|
|
US20020137181A1
(en)
*
|
2000-07-18 |
2002-09-26 |
Rachel Meyers |
14087, a novel serine protease molecule and uses therefor
|
|
AU2001293718A1
(en)
*
|
2000-08-07 |
2002-02-18 |
Bayer Aktiengesellschaft |
Regulation of human membrane-type serine protease
|
|
GB0020345D0
(en)
*
|
2000-08-17 |
2000-10-04 |
Glaxo Group Ltd |
Protein
|
|
JP2004531201A
(en)
*
|
2000-08-22 |
2004-10-14 |
レキシコン・ジェネティクス・インコーポレーテッド |
Novel human protease and polynucleotide encoding the protease
|
|
WO2002026949A2
(en)
*
|
2000-09-29 |
2002-04-04 |
Lexicon Genetics Incorporated |
Human proteases and polynucleotides encoding the same
|
|
KR100875221B1
(en)
*
|
2000-10-12 |
2008-12-19 |
페링 비.브이 |
Novel Serine Protease Gene Related to Dipipipo
|
|
WO2002051995A1
(en)
*
|
2000-12-22 |
2002-07-04 |
Millennium Pharmaceuticals, Inc. |
A human metallo protease member of the adamts family, and uses thereof
|
|
GB0101760D0
(en)
*
|
2001-01-23 |
2001-03-07 |
Glaxo Group Ltd |
Novel protein
|
|
WO2002072786A2
(en)
|
2001-03-13 |
2002-09-19 |
Corvas International, Inc. |
Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
|
|
US7172892B2
(en)
*
|
2001-03-22 |
2007-02-06 |
Dendreon Corporation |
Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon
|
|
US7034134B2
(en)
|
2001-04-26 |
2006-04-25 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
|
|
US7112430B2
(en)
*
|
2001-05-14 |
2006-09-26 |
Dendreon Corporation |
Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
|
|
AU2002319703A1
(en)
|
2001-07-27 |
2003-02-17 |
Wyeth |
Aggrecanase molecules
|
|
WO2003027282A1
(en)
*
|
2001-09-24 |
2003-04-03 |
Daiichi Fine Chemical Co., Ltd. |
Adamts-15, -16, -17, -18 and -19
|
|
AU2002351945A1
(en)
*
|
2001-11-13 |
2003-05-26 |
Universite De Liege |
A new disintegrin and metalloproteinase with thrombospondin type i repeats polynucleotide and its encoded polypeptide
|
|
AU2003238359A1
(en)
*
|
2002-01-28 |
2003-09-02 |
Bayer Aktiengesellschaft |
Regulation of human membrane-type serine protease
|
|
EP2341350B1
(en)
*
|
2003-09-20 |
2017-11-08 |
Electrophoretics Limited |
Diagnostic method for brain damage-related disorders based on detection of dj-1
|
|
US20080248462A1
(en)
*
|
2003-10-21 |
2008-10-09 |
Baayer Healhcare Ag |
Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1)
|
|
WO2005106021A1
(en)
*
|
2004-04-28 |
2005-11-10 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 8 (dpp8)
|
|
EP1751182A1
(en)
*
|
2004-05-27 |
2007-02-14 |
VIB vzw |
A novel human card-only protein that inhibits pro-il-1 beta; maturation
|
|
EP3231442B1
(en)
*
|
2006-06-23 |
2019-12-25 |
ADC Therapeutics SA |
Polynucleotides and polypeptide sequences involved in cancer
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
EP2083861A4
(en)
|
2006-11-07 |
2010-11-24 |
Merck Sharp & Dohme |
Antagonists of pcsk9
|
|
WO2008118386A2
(en)
|
2007-03-27 |
2008-10-02 |
Merck & Co., Inc. |
Method for detecting autoprocessed, secreted pcsk9
|
|
JOP20080381B1
(en)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9)
|
|
AR070315A1
(en)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
|
|
AR070316A1
(en)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
|
|
EP3130674B1
(en)
|
2008-11-03 |
2020-07-08 |
ADC Therapeutics SA |
Antibodies that specifically block the biological activity of a tumor antigen
|
|
WO2010068526A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
AU2010313324A1
(en)
|
2009-10-30 |
2012-04-12 |
Merck Sharp & Dohme Corp. |
AX213 and AX132 PCSK9 antagonists and variants
|
|
WO2011053759A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Ax1 and ax189 pcsk9 antagonists and variants
|
|
SMT201900505T1
(en)
|
2011-03-31 |
2019-11-13 |
Adc Therapeutics Sa |
Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
|
|
CN111298119A
(en)
|
2012-01-09 |
2020-06-19 |
Adc治疗股份有限公司 |
Methods for treating triple negative breast cancer and basal-like breast cancer by using inhibitors of kidney associated antigen 1(KAAG1)
|
|
KR20150023711A
(en)
|
2012-06-15 |
2015-03-05 |
제넨테크, 인크. |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
BR112015026513A2
(en)
|
2013-04-17 |
2017-07-25 |
Pfizer |
n-piperidin-3-ylbenzamide derivatives to treat cardiovascular disease
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8945560B1
(en)
|
2014-07-15 |
2015-02-03 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
WO2017220988A1
(en)
|
2016-06-20 |
2017-12-28 |
Kymab Limited |
Multispecific antibodies for immuno-oncology
|
|
EP3534947A1
(en)
|
2016-11-03 |
2019-09-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
|
WO2018119354A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Gene editing of pcsk9
|
|
EP4133072A4
(en)
|
2020-04-09 |
2024-11-06 |
Verve Therapeutics, Inc. |
CHEMICALLY MODIFIED GUIDE RNAS FOR GENOME EDITING WITH CAS9
|